Fenofibric acid

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Fenofibric Acid 是一种脂质调节剂，可作为口服延迟释放胶囊使用。

Fenofibric acid is a lipid regulating agent available as delayed release capsules for oral administration.(In Vitro):Fenofibric acid is a PPAR activitor, with EC50s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively. Fenofibric acid (10, 25, 50, 75, and 100 nM) dose-dependently inhibits COX-2 enzyme, with IC50 of 48 nM. Fenofibric acid (500 nM) reduces abundance of AOX1 protein in HepG2 cells. Fenofibric acid (100?μM) decreases JNK1/2, c-Jun, and p38 MAPK phosphorylation, and prevents the accumulation of reactive oxygen species, endoplasmic reticulum (ER) stress and disruption of blood retinal barrier (BRB) in response to the combination of high-glucose (HG) and hypoxia in ARPE-19 cells. Fenofibric acid (100?μM) activates IGF-IR/Akt/ERK1/2-mediated survival signaling pathways in ARPE-19 cells under HG conditions and hypoxia.(In Vivo):Fenofibric acid (1, 5, 10 mg/kg, p.o.) shows anti-inflammatory activity in Wistar rats with acute inflammation induced by carrageenan.

——

——

FNF Acid | NSC 281318

Metabolic Enzyme/Protease

MMP

MMP| PPARα

Other Indications

——

42017-89-0

318.75

C17H15ClO4

>98% (HPLC)

DMSO: 60 mg/mL; Water: < 1 mg/mL

CC(C)(OC1=CC=C(C(C2=CC=C(Cl)C=C2)=O)C=C1)C(O)=O

2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid

(-20℃)

With Ice Pack

≥ 2 years